查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1682229

顯影劑與注射器系統市場：2025 年至 2035 年分析與預測

Global Contrast Media Agent and Injector Systems Market: Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 120 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

全球顯影劑和注射器系統市場對於現代診斷成像至關重要，它可以在電腦斷層掃描、MRI、X 光和超音波檢查等過程中更清晰地顯示內部身體結構。

顯影劑是注射到體內的特殊物質，可以提高影像的清晰度，使醫療專業人員能夠更有效地檢測異常情況。顯影劑的使用對於各種診斷影像技術至關重要，可確保詳細且準確的診斷。隨著全球醫療保健需求的不斷成長，加上影像技術的進步，對顯影劑及其輸送系統的需求也不斷成長，鞏固了顯影劑在臨床實踐中的重要性。

有幾個因素推動了全球顯影劑和注射器系統市場的發展。首先，癌症、心血管和神經系統疾病等慢性疾病的發生率不斷上升，推動了對先進成像技術的需求，而這些技術需要顯影劑才能獲得最佳效果。根據世界衛生組織 (WHO) 統計，僅癌症每年就會導致數億人死亡，這凸顯了早期發現的必要性，而這在很大程度上依賴於顯影劑的使用。其次，3T MRI 和 4D 電腦斷層掃描等影像技術的不斷進步，需要使用更複雜、更高品質的顯影劑來提供更清晰、更詳細的影像。第三，世界人口老化將導致診斷影像的頻率增加，進一步增加對有效顯影劑的需求。最後，對提高診斷準確性和早期發現疾病的需求不斷成長，顯影劑對於醫療保健系統至關重要。

儘管存在顯著的成長動力，顯影劑和注射器系統市場仍面臨許多挑戰。主要擔心的是顯影劑的潛在副作用，包括過敏反應和腎毒性。這種安全性問題可能會限制某些顯影劑的使用，尤其是對於已有疾病的患者，從而限制其市場應用。此外，顯影劑和相關影像程序的高成本也構成了障礙，特別是在醫療預算有限的中低收入國家。此外，監管挑戰可能會減緩市場引入速度，因為獲得新顯影劑和注射系統的核准既費時又昂貴。

顯影劑和注射器系統市場存在著許多機會。隨著亞太地區和非洲部分地區等新興市場獲得診斷影像的機會不斷增加，預計醫療保健基礎設施的擴大將推動對顯影劑的需求。此外，精準醫療的興起，專注於為個別患者制定個人化治療，推動了對能夠提供準確診斷結果的更專業的顯影劑的需求。奈米技術在分子層面設計顯影劑以提供更高的精度，而人工智慧（AI）領域的創新正在改變成像系統，為市場帶來令人興奮的機會。奈米粒子顯影劑有望透過實現更高的靈敏度和更高解析度的掃描徹底改變成像技術，為醫療保健專業人員開闢新的途徑。

本報告研究了全球顯影劑和注射器系統市場，並概述了市場狀況以及按產品、應用、最終用戶和地區分類的趨勢，以及參與市場的公司概況。

目錄

執行摘要

研究範圍

第 1 章 全球顯影劑與注射器系統市場概述

  • 市場展望
  • 產業展望
  • 市場動態

2. 2024 年至 2035 年全球顯影劑和注射器系統市場規模分析（美元）

  • 市場概況
  • 成長型股市
  • 顯影劑
  • 噴射系統

3. 2024 年至 2035 年全球顯影劑和注射器系統市場規模分析（美元）

  • 市場概況
  • 成長型股市
  • 放射科
  • 心臟病學
  • 腫瘤學
  • 神經科
  • 其他（泌尿系統、胃腸科等）

4. 2024 年至 2035 年全球顯影劑和注射器系統市場規模分析（美元），按最終用戶分類

  • 市場概況
  • 成長型股市
  • 醫院
  • 診斷影像中心
  • 其他（ASC、研究機構等）

5. 2024 年至 2035 年全球顯影劑和注射器系統市場規模分析（美元），按地區分類

  • 市場概況

6. 全球顯影劑和注射器系統市場競爭基準化分析和公司概況

  • 競爭性基準化分析
  • 競爭格局
    • 各公司的主要策略和發展
    • 關鍵進展
    • 2024 年市場佔有率分析
  • 公司簡介
    • Bayer AG
    • Beijing Beilu Pharmaceutical Co. Ltd.
    • Bracco Group
    • Fresenius SE & Co. KGaA
    • FUJIFILM Holdings Corporation
    • General Electric Company
    • Guerbet
    • Jiangsu Hengrui Pharmaceutical Co., Ltd
    • Jodas Expoim Pvt. Ltd
    • Lantheus Holdings, Inc.
    • Shenzen Seacrown Electromechanical Co., Ltd
    • Sino Medical-Device Technology Co., Ltd
    • ulrich GmbH & Co. KG
    • Unijules Life Sciences Ltd
    • 其他主要企業
簡介目錄
Product Code: BHR1401SB

Global Contrast Media Agent and Injector System Market Industry Overview

The global contrast media agent and injector system market is integral to modern diagnostic imaging, providing enhanced visualization of internal body structures during procedures like CT scans, MRIs, X-rays, and ultrasounds. Contrast media agents are specialized substances injected into the body to improve the clarity of images, allowing healthcare professionals to detect abnormalities more effectively. The use of contrast media agents is crucial for a variety of imaging techniques, ensuring detailed and accurate diagnostics. As healthcare needs increase globally, coupled with advancements in imaging technology, the demand for contrast media agents and their delivery systems is rising, solidifying their importance in clinical practice.

Several factors are driving the global contrast media agent and injector system market. First, the growing prevalence of chronic diseases, such as cancer, cardiovascular disease, and neurological disorders, has elevated the demand for advanced imaging technologies that require contrast media agents for optimal results. According to the World Health Organization (WHO), cancer alone accounts for millions of deaths each year, emphasizing the need for early detection, which heavily relies on the use of contrast media agents. Second, continuous advancements in imaging technologies, such as 3T MRIs and 4D CT scans, necessitate the use of more sophisticated and higher-quality contrast media agents to deliver clearer, more detailed images. Third, the aging global population is leading to an increased frequency of diagnostic imaging procedures, further boosting the need for effective contrast media agents. Lastly, the rising demand for greater diagnostic accuracy and early disease detection is making contrast media agents indispensable in the healthcare system.

Despite the substantial growth drivers, the contrast media agent and injector system market for contrast media agents faces several challenges. A major concern is the potential for adverse reactions to contrast media agents, including allergic reactions or nephrotoxicity. These safety concerns can restrict the use of certain contrast media agents, particularly in patients with pre-existing conditions, which in turn limits their market adoption. Furthermore, the high cost of contrast media agents and the associated imaging procedures can act as a barrier, especially in low- and middle-income countries where healthcare budgets are more constrained. Regulatory hurdles also pose challenges, as obtaining approval for new contrast media agents and injector systems can be a lengthy and costly process, delaying their introduction to the market.

The contrast media agent and injector system market presents numerous opportunities. The growing healthcare infrastructure in emerging markets, such as Asia-Pacific and parts of Africa, is expected to boost demand for contrast media agents as these regions expand access to diagnostic imaging. Additionally, the rise of precision medicine, which focuses on tailoring treatments to individual patients, is driving the demand for more specialized contrast media agents that can provide precise diagnostic results. Innovations in nanotechnology, where contrast media agents are designed at the molecular level to offer higher precision, and artificial intelligence (AI), which is transforming imaging systems, present exciting opportunities for the market. Nanoparticle-based contrast media agents are expected to revolutionize imaging techniques by enabling higher sensitivity and resolution in scans, opening new avenues for healthcare professionals.

Global Contrast Media Agent and Injector System Market Lifecycle Stage

The global contrast media agent and injector system market is experiencing significant growth, with multiple collaborations between key market players aimed at combining resources, expanding customer bases, and enhancing marketing efforts. This growth is further supported by continuous research and development focused on creating innovative products. Additionally, many pharmaceutical companies are broadening their operations and becoming more outsourcing-oriented, which is helping to drive the expansion of the contrast media agent and injector system market.

Industry and Technology Overview

Market Segmentation:

Segmentation 1: by Product

  • Contrast Media Agents
  • Injector Systems

The global contrast media agent and injector system market (by product) is expected to be dominated by the contrast media agents segment.

  • Contrast Media Agents (by Modality)
    • X-Ray/CT Scan
    • MRI
    • Ultrasound

The global contrast media agent market (by modality) is expected to be dominated by the X-Ray/CT scan.

  • Contrast Media Agents (by Type of Media Agent)
    • Iodine-Based Contrast Media Agent
    • Gadolinium-Based Contrast Media Agent
    • Barium-Based Contrast Media Agent
    • Microbubble Contrast Media Agent
    • Others

The global contrast media agent market (by type of media agent) is expected to be dominated by iodine-based contrast media agent.

  • Injector Systems (by Modality)
    • CT Injector Systems
    • MRI Injector Systems
    • Cardiovascular/Angiography Injector Systems

The global contrast media injector system market (by modality) is expected to be dominated by CT injector systems.

  • Injector Systems (by Product)
    • Injector
    • Consumables and Accessories

The global contrast media injector system market (by product) is expected to be dominated by consumables and accessories.

  • Injector Systems (by Injector Type)
    • Single-Head Injectors
    • Dual-Head Injectors
    • Syringeless Injectors

The global contrast media injector system market (by injector type) is expected to be dominated by single-head injectors.

Segmentation 2: by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

The global contrast media agent and injector system market (by region) is dominated by the North America region.

Recent Developments in Global Contrast Media Agent and Injector System Market

  • In January 2023, Bayer AG received European approval for its iodine-based contrast agents, Ultravist-300 and Ultravist-370, for use in contrast-enhanced mammography (CEM).
  • In December 2022, Beijing Beilu Pharmaceutical Co. Ltd. expanded its operations by establishing a wholly-owned subsidiary in Hong Kong.
  • In April 2022, Beijing Beilu Pharmaceutical Co., Ltd. received the ""Drug Registration Certificate"" from the National Medical Products Administration (NMPA) for its gadobutrol injection.
  • In February 2023, Bracco Group formed a partnership with Wellstar Health System to conduct trials for its FDA-approved VUEWAY (gadopiclenol) injection, a contrast agent designed for MRI applications.
  • In February 2023, Bracco Group acquired all shares of Bracco-Eisai from Eisai and subsequently rebranded the company as Bracco Japan, Ltd.
  • In July 2022, Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA, launched its line of generic contrast media agents in the U.S.
  • In December 2022, General Electric Company partnered with ulrich GmbH & Co. KG to introduce a branded multi-dose contrast media injector in the U.S. market.

Demand - Drivers and Limitations

The following are the drivers for the global contrast media agent and injector system market:

  • Increasing prevalence of cancer and cardiovascular diseases leading to an upsurge in demand for imaging with contrast media agent and injector system
  • Upsurge in demand for image-guided diagnostics
  • Growing number of regulatory approvals

The global contrast media agent and injector system market is expected to face some limitations as well due to the following challenges:

  • Rising health concerns post usage of contrast media agents in the body

How can this report add value to an organization?

Growth/Marketing Strategy: The global contrast media agent and injector system market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint ventures.

Competitive Strategy: The global contrast media agent and injector system market consists of various leading manufacturers, small-medium enterprises, and emerging startups. With the increasing demand for advanced devices, companies have the opportunity to expand their presence in the market through different strategic approaches. Some of the strategies followed by the leading contributors are the launch of new products, mergers and acquisitions, and regulatory and legal approvals.

Competitive Landscape

The contrast media agent and injector system market is highly competitive, with major players focusing on product innovation and strategic expansion.

Contrast Media Agent And Injector System Key Market Players and Competition Synopsis:

  • Bayer AG
  • Fresenius SE & Co. KGaA
  • FUJIFILM Visualsonics, Inc (Fujifilm Holdings Corporation)
  • General Electric Company
  • Lantheus Medical Imaging
  • Guerbet
  • Bracco Group
  • J.B. Chemicals and Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • ulrich GmbH & Co. KG
  • ShenzenSeacrown Electromechanical Co Ltd
  • Jodas Expoim Pvt. Ltd.
  • Beijing Beilu Pharmaceutical Co. Ltd
  • MEDTRON AG
  • SINO MDT
  • Stanex Drugs & Chemical Pvt. Ltd.
  • Taejoon Pharm
  • Nano Therapeutics Pvt. Ltd.
  • Nemoto Kyorindo Co., Ltd.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Global Contrast Media Agent and Injector Systems Market Overview

  • 1.1 Market Outlook
    • 1.1.1 Definitions
    • 1.1.2 Inclusion and Exclusion Criteria
    • 1.1.3 Market Size, 2024 - 2035 (US$)
    • 1.1.4 Market Growth Scenario
      • 1.1.4.1 Realistic Scenario
      • 1.1.4.2 Optimistic Scenario
      • 1.1.4.3 Pessimistic Scenario
  • 1.2 Industry Outlook
    • 1.2.1 Market Overview
    • 1.2.2 Market Ecosystem
    • 1.2.3 Regulatory Landscape
      • 1.2.3.1 Regulatory and Legal Requirements and Framework in the U.S.
      • 1.2.3.2 Regulatory and Legal Requirements and Framework in Europe
      • 1.2.3.3 Regulatory and Legal Requirements and Framework in Asia-Pacific
      • 1.2.3.4 Regulatory and Legal Requirements and Framework in Other Key Countries
    • 1.2.4 Patent Analysis
      • 1.2.4.1 Patent Filing Trend (by Year)
      • 1.2.4.2 Patent Filing Trend (by Country)
  • 1.3 Market Dynamics
    • 1.3.1 Market Key Trends
    • 1.3.2 Market Drivers
      • 1.3.2.1 Impact Analysis
    • 1.3.3 Market Restraints
      • 1.3.3.1 Impact Analysis
    • 1.3.4 Market Opportunities
      • 1.3.4.1 Impact Analysis

2. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Product Type

  • 2.1 Market Overview
  • 2.2 Growth Share Market
  • 2.3 Contrast Media Agent
    • 2.3.1 By Modality
      • 2.3.1.1 X-Ray/CT scan
      • 2.3.1.2 MRI
      • 2.3.1.3 Ultrasound
    • 2.3.2 By Type of Media Agent
      • 2.3.2.1 Iodine-Based Contrast Media Agent
      • 2.3.2.2 Gadolinium-Based Contrast Media Agent
      • 2.3.2.3 Barium-Based Contrast Media Agent
      • 2.3.2.4 Microbubble Contrast Media Agent
      • 2.3.2.5 Others
  • 2.4 Injector System
    • 2.4.1 By Product
      • 2.4.1.1 Injector
      • 2.4.1.2 Consumable and Accessories
    • 2.4.2 By Modality
      • 2.4.2.1 CT Injector Systems
      • 2.4.2.2 MRI Injector Systems
      • 2.4.2.3 Cardiovascular/Angiography Injector Systems
    • 2.4.3 By Injector Type
      • 2.4.3.1 Single Head Injectors
      • 2.4.3.2 Dual Head Injectors
      • 2.4.3.3 Syringeless Injectors

3. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Application

  • 3.1 Market Overview
  • 3.2 Growth Share Market
  • 3.3 Radiology
  • 3.4 Cardiology
  • 3.5 Oncology
  • 3.6 Neurology
  • 3.7 Others (Urology, Gastroenterology, etc.)

4. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by End User

  • 4.1 Market Overview
  • 4.2 Growth Share Market
  • 4.3 Hospitals
  • 4.4 Diagnostic Imaging Centers
  • 4.5 Others (ASCs, Research Institutes, etc.)

5. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Region

  • 5.1 Market Overview
    • 5.1.1 Market Dynamics
    • 5.1.2 Market Size and Forecast
      • 5.1.2.1 North America Contrast Media Agent and Injector Systems Market
        • 5.1.2.1.1 Key Findings
        • 5.1.2.1.2 Market Dynamics
        • 5.1.2.1.3 Impact Analysis
        • 5.1.2.1.4 Market Sizing and Forecast
          • 5.1.2.1.4.1 North America Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.1.4.2 North America Contrast Media Injector System Market (by Product)
          • 5.1.2.1.4.3 North America Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.1.4.3.1 U.S.
          • 5.1.2.1.4.3.1.1 U.S. Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.1.4.3.1.2 U.S. Contrast Media Injector System Market (by Product)
          • 5.1.2.1.4.3.2 Canada.
          • 5.1.2.1.4.3.2.1 Canada Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.1.4.3.2.2 Canada Contrast Media Injector System Market (by Product)
      • 5.1.2.2 Europe Contrast Media Agent and Injector Systems Market
        • 5.1.2.2.1 Key Findings
        • 5.1.2.2.2 Market Dynamics
        • 5.1.2.2.3 Impact Analysis
        • 5.1.2.2.4 Market Sizing and Forecast
          • 5.1.2.2.4.1 Europe Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.2 Europe Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3 Europe Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.2.4.3.1 U.K.
          • 5.1.2.2.4.3.1.1 U.K. Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.1.2 U.K. Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.2 Germany.
          • 5.1.2.2.4.3.2.1 Germany Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.2.2 Germany Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.3 France
          • 5.1.2.2.4.3.3.1 France Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.3.2 France Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.4 Italy
          • 5.1.2.2.4.3.4.1 Italy Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.4.2 Italy Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.5 Spain
          • 5.1.2.2.4.3.5.1 Spain. Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.5.2 Spain Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.6 Rest of Europe.
          • 5.1.2.2.4.3.6.1 Rest of Europe Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.6.2 Rest of Europe Contrast Media Injector System Market (by Product)
      • 5.1.2.3 Asia-Pacific Contrast Media Agent and Injector Systems Market
        • 5.1.2.3.1 Key Findings
        • 5.1.2.3.2 Market Dynamics
        • 5.1.2.3.3 Impact Analysis
        • 5.1.2.3.4 Market Sizing and Forecast
          • 5.1.2.3.4.1 Asia-Pacific Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.2 Asia-Pacific Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3 Asia-Pacific Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.3.4.3.1 China
          • 5.1.2.3.4.3.1.1 China Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.1.2 China Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.2 Japan
          • 5.1.2.3.4.3.2.1 Japan Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.2.2 Japan Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.3 India
          • 5.1.2.3.4.3.3.1 India Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.3.2 India Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.4 Australia
          • 5.1.2.3.4.3.4.1 Australia Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.4.2 Australia Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.5 South Korea
          • 5.1.2.3.4.3.5.1 South Korea Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.5.2 South Korea Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.6 Rest-of- Asia-Pacific
          • 5.1.2.3.4.3.6.1 Rest-of-Asia-Pacific Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.6.2 Rest-of-Asia-Pacific Contrast Media Injector System Market (by Product)
      • 5.1.2.4 Latin America Contrast Media Agent and Injector Systems Market
        • 5.1.2.4.1 Key Findings
        • 5.1.2.4.2 Market Dynamics
        • 5.1.2.4.3 Impact Analysis
        • 5.1.2.4.4 Market Sizing and Forecast
          • 5.1.2.4.4.1 Latin America Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.2 Latin America Contrast Media Injector System Market (by Product)
          • 5.1.2.4.4.3 Latin America Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.4.4.3.1 Brazil
          • 5.1.2.4.4.3.1.1 Brazil Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.3.1.2 Brazil Contrast Media Injector System Market (by Product)
          • 5.1.2.4.4.3.2 Mexico
          • 5.1.2.4.4.3.2.1 Mexico Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.3.2.2 Mexico Contrast Media Injector System Market (by Product)
          • 5.1.2.4.4.3.3 Rest-of-Latin America
          • 5.1.2.4.4.3.3.1 Rest-of-Latin America Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.3.3.2 Rest-of-Latin America Contrast Media Injector System Market (by Product)
      • 5.1.2.5 Middle East and Africa Contrast Media Agent and Injector Systems Market
        • 5.1.2.5.1 Key Findings
        • 5.1.2.5.2 Market Dynamics
        • 5.1.2.5.3 Impact Analysis
        • 5.1.2.5.4 Market Sizing and Forecast
          • 5.1.2.5.4.1 Middle East and Africa Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.2 Middle East and Africa Contrast Media Injector System Market (by Product)
          • 5.1.2.5.4.3 Middle East and Africa Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.5.4.3.1 UAE
          • 5.1.2.5.4.3.1.1 UAE Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.3.1.2 UAE Contrast Media Injector System Market (by Product)
          • 5.1.2.5.4.3.2 South Africa
          • 5.1.2.5.4.3.2.1 South Africa Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.3.2.2 South Africa Contrast Media Injector System Market (by Product)
          • 5.1.2.5.4.3.3 Rest-of-MEA
          • 5.1.2.5.4.3.3.1 Rest-of-Middle East and Africa Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.3.3.2 Rest-of-Middle East and Africa Contrast Media Injector System Market (by Product)

6. Global Contrast Media Agent and Injector Systems Market- Competitive Benchmarking and Company Profiles

  • 6.1 Competitive Benchmarking
  • 6.2 Competitive Landscape
    • 6.2.1 Key Strategies and Developments by Company
      • 6.2.1.1 Funding Activities
      • 6.2.1.2 Mergers and Acquisitions
      • 6.2.1.3 Regulatory Approvals
      • 6.2.1.4 Partnerships, Collaborations, and Business Expansions
    • 6.2.2 Key Developments Analysis
    • 6.2.3 Market Share Analysis, 2024
  • 6.3 Company Profiles
    • 6.3.1 Bayer AG
      • 6.3.1.1 Company Overview
      • 6.3.1.2 Product Portfolio/Offering
      • 6.3.1.3 Key Competitors
      • 6.3.1.4 Analyst View
    • 6.3.2 Beijing Beilu Pharmaceutical Co. Ltd.
      • 6.3.2.1 Company Overview
      • 6.3.2.2 Product Portfolio/Offering
      • 6.3.2.3 Key Competitors
      • 6.3.2.4 Analyst View
    • 6.3.3 Bracco Group
      • 6.3.3.1 Company Overview
      • 6.3.3.2 Product Portfolio/Offering
      • 6.3.3.3 Key Competitors
      • 6.3.3.4 Analyst View
    • 6.3.4 Fresenius SE & Co. KGaA
      • 6.3.4.1 Company Overview
      • 6.3.4.2 Product Portfolio/Offering
      • 6.3.4.3 Key Competitors
      • 6.3.4.4 Analyst View
    • 6.3.5 FUJIFILM Holdings Corporation
      • 6.3.5.1 Company Overview
      • 6.3.5.2 Product Portfolio/Offering
      • 6.3.5.3 Key Competitors
      • 6.3.5.4 Analyst View
    • 6.3.6 General Electric Company
      • 6.3.6.1 Company Overview
      • 6.3.6.2 Product Portfolio/Offering
      • 6.3.6.3 Key Competitors
      • 6.3.6.4 Analyst View
    • 6.3.7 Guerbet
      • 6.3.7.1 Company Overview
      • 6.3.7.2 Product Portfolio/Offering
      • 6.3.7.3 Key Competitors
      • 6.3.7.4 Analyst View
    • 6.3.8 Jiangsu Hengrui Pharmaceutical Co., Ltd
      • 6.3.8.1 Company Overview
      • 6.3.8.2 Product Portfolio/Offering
      • 6.3.8.3 Key Competitors
      • 6.3.8.4 Analyst View
    • 6.3.9 Jodas Expoim Pvt. Ltd
      • 6.3.9.1 Company Overview
      • 6.3.9.2 Product Portfolio/Offering
      • 6.3.9.3 Key Competitors
      • 6.3.9.4 Analyst View
    • 6.3.10 Lantheus Holdings, Inc.
      • 6.3.10.1 Company Overview
      • 6.3.10.2 Product Portfolio/Offering
      • 6.3.10.3 Key Competitors
      • 6.3.10.4 Analyst View
    • 6.3.11 Shenzen Seacrown Electromechanical Co., Ltd
      • 6.3.11.1 Company Overview
      • 6.3.11.2 Product Portfolio/Offering
      • 6.3.11.3 Key Competitors
      • 6.3.11.4 Analyst View
    • 6.3.12 Sino Medical-Device Technology Co., Ltd
      • 6.3.12.1 Company Overview
      • 6.3.12.2 Product Portfolio/Offering
      • 6.3.12.3 Key Competitors
      • 6.3.12.4 Analyst View
    • 6.3.13 ulrich GmbH & Co. KG
      • 6.3.13.1 Company Overview
      • 6.3.13.2 Product Portfolio/Offering
      • 6.3.13.3 Key Competitors
      • 6.3.13.4 Analyst View
    • 6.3.14 Unijules Life Sciences Ltd
      • 6.3.14.1 Company Overview
      • 6.3.14.2 Product Portfolio/Offering
      • 6.3.14.3 Key Competitors
      • 6.3.14.4 Analyst View
    • 6.3.15 Other Key Companies